Page 86 - Haematologica May 2022

A.M. Evens et al.
ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2020;7(11):e808- e815.
28. Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET- CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419-2429.
29. Spinner MA, Advani RH. Risk-adapted ther- apy for advanced-stage Hodgkin lym- phoma. Hematology Am Soc Hematol Educ Program. 2018;2018(1):200-206.
30. ClinicalTrials.gov. HD21 for Advanced Stages. NCT02661503. [last accessed May 18, 2021]; Available from: https:// clinicaltri- als.gov/ct2/show/NCT02661503?term=HD 21&cond=Hodgkin+Lymphoma&draw=2& rank=1.
31. Eichenauer DA, Plütschow A, Kreissl S, et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical
Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncol. 2017; 18(12):1680-1687.
32. van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4(4):458-465.
33. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016; 8(4):659-671.
34. Addington J, Freimer M. Chemotherapy- induced peripheral neuropathy: an update on the current understanding. F1000Res. 2016;5:F1000 Faculty Rev-1466.
35. Radford J, Connors JM, Younes A, et al. Resolution of peripheral neuropathy (PN) in patients who received A+AVD or ABVD in the phase 3 ECHELON-1 trial. Blood. 2018; 132(Suppl 1):2921.
36. Straus D, Collins G, Walewski J, et al. Primary prophylaxis with G-CSF may
improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leuk Lymphoma. 2020; 61(12):2931-2938.
37. Sureda A, Domingo-Domenech E, Gautam A. Neutropenia during frontline treatment of advanced Hodgkin lymphoma: incidence, risk factors, and management. Crit Rev Oncol Hematol. 2019;138:1-5.
38. Straus DJ, Collins GP, Walewski JA, et al. Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma. J Clin Oncol. 2018; 36(Suppl 15):7534.
39. Battisti WP, Wager E, Baltzer L, et al. Good Publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461- 464.
1094
haematologica | 2022; 107(5)